Cogent Biosciences Inc.
July 07, 2025 - by Joey Ramson
Biotech company $COGT is up today on the announcement of positive top-line results from Part 2 of the SUMMIT clinical trial for bezuclastinib in non-advanced systemic mastocytosis. It’s currently trading right below $10 which looks to be a resistance level. A break above today would look bullish.
